TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Grand Pharmaceutical Group Limited ( (HK:0512) ).
Grand Pharmaceutical Group Limited announced that its associate company, Sirtex Medical Pty Ltd, received early FDA approval for a new indication of its SIR-Spheres® Y-90 resin microsphere injection, now approved for treating unresectable hepatocellular carcinoma (HCC). This approval highlights the company’s strong clinical registration capabilities and supports its strategy to expand its nuclear medicine offerings globally, reinforcing its leadership in the industry. The product, which has been widely adopted and recognized for its effectiveness, is expected to enhance the company’s market position and provide significant growth opportunities.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited operates in the pharmaceutical industry, focusing on innovative nuclear medicine products. The company emphasizes research and development, leveraging a global strategic plan for nuclear medicine to create a comprehensive ecosystem that integrates diagnosis and treatment across domestic and international markets.
Average Trading Volume: 31,403,985
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.72B
For a thorough assessment of 0512 stock, go to TipRanks’ Stock Analysis page.